{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020108","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.576379+00:00","generated_at":"2026-06-24T05:58:56.542178+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"C4 Therapeutics appoints Laura Bessen, M.D. and Donna Grogan, M.D. to board of directors","bullets":["Drs. Bessen and Grogan elected as directors effective July 29, 2022; Grogan Class I, Bessen Class II.","Each granted stock options for 41,200 shares under 2020 plan; one-third vests at year one, remainder quarterly.","Bessen brings two decades of medical affairs and clinical development expertise; Grogan over 25 years in drug development and regulatory strategy.","Appointments support C4T's evolution as it advances two clinical-stage programs and prepares additional candidates.","No reportable related-party transactions or arrangements per Item 404(a) of Regulation S-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020108","json":"https://secwatch.observer/filing/0001628280-22-020108.json","markdown":"https://secwatch.observer/filing/0001628280-22-020108.md","text":"https://secwatch.observer/filing/0001628280-22-020108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/0001628280-22-020108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/cccc-20220729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:58:56.542178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00ff64f97f","claim":"Laura Bessen, M.D. was elected as Director at C4 Therapeutics, Inc..","evidence_excerpt":"On July 29, 2022, the Company’s Board of Directors (the “ Board ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Donna Grogan, M.D. and Laura Bessen, M.D, as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/0001628280-22-020108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7fc7b816f1","claim":"Donna Grogan, M.D. was elected as Director at C4 Therapeutics, Inc..","evidence_excerpt":"On July 29, 2022, the Company’s Board of Directors (the “ Board ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Donna Grogan, M.D. and Laura Bessen, M.D, as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022020108/0001628280-22-020108-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}